Effects of enalapril, losartan, and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat

Hypertension

Volumn 29, Issue 6, 1997, Pages 1260-1264

  Rosenthal, Talma ^a,b   Erlich, Yael ^a,b   Rosenmann, Eliezer ^c   Cohen, Aharon ^c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY   (Israel)

Author keywords

diabetes mellitus, experimental; enalapril; losartan; rats; verapamil

Indexed keywords

ENALAPRIL; LOSARTAN; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MONITORING; DATA ANALYSIS; DIABETES MELLITUS; DRUG EFFECT; GENETIC PREDISPOSITION; GLUCONEOGENESIS; GLUCOSE METABOLISM; HYPERINSULINEMIA; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT PLANNING;

EID: 0030921351     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.6.1260     Document Type: Article

References (63)

1. Lachaal M, Jung CY. Insulin resistance and hypertension. Mol Cell Biochem. 1992;109:119-125.
2. Cohen AM, Rosenmann E, Rosenthal T. The Cohen diabetic (non-insulin-dependent) hypertensive rat model: description of the model and pathologic findings. Am J Hypertens. 1993;6:989-995.
3. Santoro D, Natali A, Palombo C, Brandi LS, Piatti M, Ghione S, Ferrannini E. Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension. 1992;20:181-191.
4. Bell DSH. Hypoglycemia induced by enalapril in patients with insulin resistance and NIDDM. Diabetes Care. 1992;15:934-936.
5. Torlone E, Britta M, Rambotti AM, Periello G, Santeusanio F, Brunetti P, Bolli GB. Improved insulin action and glycemic control after long-term angiotensin converting enzyme inhibition in subjects with arterial hypertension and type II diabetes. Diabetes Care. 1993;16:1347-1355.
6. Gambardella S, Frontoni S, Pellegrinotti M, Testa G. Carbohydrate metabolism in hypertension: influence of treatment. J Cardiovasc Pharmacol. 1993;22(suppl 6):S87-S97.
7. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PB. Nonpeptide angiotensin II receptor antagonists, IX: antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990; 25:726-732.
8. Mizuno K, Njimura S, Tani M, Haga H, Gomibuchi T, Sanada H, Fukuchi S. Antihypertensive and hormonal activity of MK 954 in spontaneously hypertensive rats. Eur J Pharmacol. 1992;215: 305-308.
9. Bovee KC, Wong PC, Timmermans PB, Thoolen MS. Effects of the nonpeptide angiotensin II receptor antagonist DuP753 on blood pressure and renal functions in spontaneously hypertensive dogs. Am J Hypertens. 1991;4:327S-333S.
10. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, Maggon K, Shum L, Timmermans PB, Brunner HR. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation. 1991;83:1333-1342.
11. Kam KL, Pfaffendorf M, Van-Zwieten PA. Drug induced endothelium dependent and independent relaxations in isolated resistance vessels taken from simultaneously hypertensive and streptozotocin diabetic rats. Blood Pressure. 1994;3:418-427.
12. Pijl AJ, van der Wal AC, Mathy MJ, Kam KL, Hendriks MG, Pfaffendorf M, van Zwieten PA. Streptozotocin induced diabetes mellitus in spontaneously hypertensive rats: a pathophysiological model for combined effects of hypertension and diabetes. J Phamacol Toxicol Methods. 1994;32:225-233.
13. Dai S, Lee S, Battell M, McNeill JH. Cardiovascular and metabolic changes in spontaneously hypertensive rats following Streptozotocin administration. Can J Cardiol. 1994;10:562-570.
14. Chen S, Yuan CM, Haddy FJ, Pamnani MB. Effects of administration of insulin on streptozotocin induced diabetic hypertension rat. Hypertension. 1994;23:1046-1050.
15. Kusaka-Nakamura M, Kishi K, Miyazawa A, Yagi S, Sokabe H. Antihypertensive treatment in spontaneously hypertensive rats with streptozotocin induced diabetes mellitus. Acta Physiol Hung. 1988; 71:251-269.
16. Kasiske BL, O'Donnell MP, Keane WS. Zucker rat model of obesity, insulin resistance, hyperlipidemia and renal injury. Hypertension. 1992;19(suppl I):I-110-I-115.
17. Yamori Y, Ohtaka M, Nara HR, Ooshima A, Endo T. Experimental and clinical studies on the relationship between genetic hypertension and glucose metabolism. Shimane J Med Sci. 1978;2: 124-132.
18. Mondon EC, Reaven GM. Evidence of abnormalities of insulin metabolism in rats with spontaneous hypertension. Metabolism. 1988;37:303-305.
19. Cohen AM, Teitelbaum A, Saliternik R. Genetics and diet as factors in development of diabetes mellitus. Metabolism. 1972;21: 235-240.
20. Hallfrisch J, Lazar R, Jorgensen C, Reiser S. Insulin and glucose responses in rats fed sucrose or starch. Am J Clin Nutr. 1979;32: 787-793.
21. Bunag RD, Tomita T, Sasaki S. Chronic sucrose ingestion induces mild hypertension and tachycardia in rats. Hypertension. 1983;5: 218-225.
22. Young JB, Landsberg L. Effect of oral sucrose on blood pressure in the spontaneously hypertensive rat. Metabolism. 1981;30:421-424.
23. Preuss MB, Preuss HG. The effects of sucrose and sodium on blood pressure in various substrains of Wistar rats. Lab Invest. 1980;43: 101-107.
24. Stein PP, Black HR. Drug treatment of hypertension in patients with diabetes mellitus. Diabetes Care. 1991;14:425-448.
25. Barnett AH. Diabetes and hypertension. Br Med Bull. 1994;50: 397-407.
26. Donnelly R. Angiotensin converting enzyme inhibitors and insulin sensitivity: metabolic effects in hypertension, diabetes and heart failure. J Cardiovasc Phamacol. 1992;20(suppl 11):S38-S44.
27. Passa P, Le Blanc H, Marre M. Effects of enalapril in insulin dependent diabetic subjects with mild to moderate uncomplicated hypertension. Diabetes Care. 1987;10:200-204.
28. Andronico G, Angiler G, Piazza G, Gerasola G. Metabolic effects of enalapril and nifedipine in diabetic hypertensives. J Hypertens. 1991;9:S408-S409.
29. Ferrier C, Ferrari P, Wiedmann P, Keller U, Berretta-Piccoli C, Reisin WF. Antihypertensive therapy with CA+2 antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. Diabetes Care. 1991;14:911-914.
30. Paolisso G, Gambardella A, Verza M, D'Amore A, Sgambato S, Varricchio M. ACE inhibition improves insulin sensitivity in aged insulin resistant hypertensive patients. J Hum Hypertens. 1992;6: 175-179.
31. Moore MP, Elliott TW, Nicholls MG. Hormonal and metabolic effects of enalapril treatment in hypertensive subjects with NIDDM. Diabetes Care. 1988;11:397-401.
32. Prince MJ, Stuart CA, Padia M, Bandi Z, Holland B. Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patient: enalapril for hypertensive diabetics. Arch Intern Med. 1988;148:2363-2368.
33. Ferrier M, Lachkar H, Richard JL, Bringer J, Orsetti A, Miroure J. Captopril and insulin sensitivity. Ann Intern Med. 1985;102:134-135.
34. Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P. Hypoglycemia induced by angiotensin converting enzyme inhibitors in patients with non-insulin-dependent diabetes mellitus receiving sulfonylurea therapy. Am J Med. 1990;89:811-813.
35. Baba T, Neugebauer S. The link between insulin resistance and hypertension: effects of antihypertensive and antihyperlipidaemic drugs on insulin sensitivity. Drugs. 1994;47:383-404.
36. Seefeldt T, Orskov L, Mengel A, Rasmussen O, Pedersen MM, Christiansen JS. Lack of effects of angiotensin converting enzyme inhibitors (ACE) on glucose metabolism in type I diabetes. Diabet Med. 1990;7:700-704.
37. Shamiss A, Carroll J, Grossman E, Rosenthal T. The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. Am J Hypertens. 1995;8:276-281.
38. Erlich Y, Rosenthal T. Effect of angiotensin converting enzyme inhibitors on fructose induced hypertension and hyperinsulinaemia in rats. Clin Exp Pharmacol Physiol Suppl. 1995:21-23.
39. Rosenthal T, Erlich Y, Rosenmann E, Grossman E, Cohen A. Enalapril improves glucose tolerance in two rat models: a new hypertensive diabetic strain and a fructose induced hyperinsulinaemia rat. Clin Exp Pharmacol Physiol Suppl. 1995:27-28.
40. Rett K, Jacob S, Wicklmayer M. Possible synergistic effect of ACE inhibition and calcium channel blockade on insulin sensitivity in insulin resistant type II diabetic hypertensive patients. J Cardiovasc Pharmacol. 1994;23(suppl 1):S29-S33.
41. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868-873.
42. Bao G, Gohlke P, Qadri F, Unger T. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension. 1992;20:74-79.
43. Erlich Y, Rosenthal T. Contribution of bradykinin (BK) to the beneficial effects of CEI in fructose induced hyperinsulinemic rat. In: Abstracts of the 16th Scientific Meeting of the International Society of Hypertension; June 23-27, 1996: Glasgow, UK; p. 857.
44. Moan A, Risanger T, Eide I, Kjeldsen SE. The effect of angiotensin receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Pressure. 1994;3: 185-188.
45. Remuzzi A, Perico N, Amuchastegui CS, Malanchini Mazerska M, Bottaglia C, Bertani T, Remuzzi G. Short and long term effect of angiotensin II receptor blockade in rats with experimental diabetes. Diabetes. 1993;4:40-49.
46. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1992;90:766-771.
47. Imamura A, Mackenzie HS, Lacy ER, Hutchison FN, Fitzgibbon WR, Ploth DW. Effects of chronic treatment with angiotensin converting enzyme inhibitor or an angiotensin receptor antagonist in two-kidney, one-clip hypertensive rats. Kidney Int. 1995;47: 1394-1402.
48. Sakemi T, Baba N. Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats. Nephron. 1993;65:426-432.
49. Tomiyama H, Kushior T, Abeta H, Ishii T, Takahashi A., Luzia F, Tomoko A, Toru H, Fumio F, Yuji O, Hitoshi K, Fumiyuki K, Katsuo K, Nagao K. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitors. Hypertension. 1994;23:450-455.
50. Weidmann P, Trost BN, Ferrari P. Treatment of the hypertensive diabetic: focus on calcium channel blockade. In: Omae T, Zanchetti A, eds. How Should Elderly Hypertensive Patients Be Treated? Tokyo, Japan: Springer-Verlag; 1989:85-99.
51. Weidmann P, Boehlen LM, de Courter M. Pathogenesis and treatment of hypertension associated with diabetes mellitus. Am Heart J. 1993;125:1498-1513.
52. Hermansen K, Iversen J. Effect of verapamil on pancreatic glucagon release from the isolated perfused canine pancreas. Scand J Clin Lab Invest. 1977;37:139-142.
53. Dominic J, Miller RE, Anderson J, McAllister R. Pharmacology of verapamil, II: impairment of glucose tolerance by verapamil in conscious dog. Pharmacology. 1980;20:196-202.
54. Kaymaz AA, Tan H, Altug T, Bucukdevrim AS. The effects of calcium channel blockers, verapamil, nifedipine and diltiazem on metabolic control in diabetic rats. Diabetes Res Clin Pract. 1995;28: 201-205.
55. Chellingsworth MC, Kendall MJ, Wright AD, Pasi S, Pasi J. The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin dependent diabetes mellitus. J Hum Hypertens. 1989;3:35-39.
56. Semple CG, Thomson JA, Beastall GH, Lorimar AR. Oral verapamil does not affect glucose tolerance in nondiabetics. Br J Clin Pharmacol. 1983;15:570-571.
57. Semple CG, Omile C, Buchanan KD, Beastall GH, Paterson KR. Effect of oral verapamil on glibenclamide stimulated insulin secretion. Br J Clin Pharmacol. 1986;22:187-190.
58. Whitcroft I. Do antihypertensive drugs precipitate diabetes? Br Med J. 1985;290:322.
59. Cruickshank JK, Anderson NMcF, Wadsworth J, Young SM, Jepson E. Treating hypertension in black compared with white non-insulin-dependent diabetes: a double blind trial of verapamil and metoprolol. Br Med J. 1988;297:1155-1159.
60. Trost BN. Hypertension in the diabetic patient: selection and optimum use of antihypertensive drugs. Drugs. 1989;38:621-633.
61. Andersson DEH, Rojdmark S. Improvement of glucose tolerance by verapamil in patients with non-insulin-dependent diabetes mellitus. Acta Med Scand. 1981;210:27-33.
62. Sorensen MB, Sjostrand H, Sengelov H, Thrane MT, Holst JJ, Lyngsoe J. Influence of short term verapamil treatment on glucose metabolism in patients with non-insulin dependent diabetes mellitus. Eur J Clin Pharmacol. 1991;41:401-404.
63. Lyngsoe J, Busch Sorensen M, Sjorstrand H, Sengelov H, Tiefenthal-Thrane M, Juul Holst J. The effect of sustained release verapamil on glucose metabolism in patients with non-insulin-dependent diabetes mellitus. Drugs. 1992;44(suppl 1):85-87.